5-LOX

5-LOX (ALOX5) catalyzes two steps in leukotriene biosynthesis from arachidonic acid, placing it at the center of inflammatory lipid mediator production[1]. Mechanistically, 5-LOX converts arachidonic acid toward LTA4, which supports formation of LTB4 and cysteinyl leukotrienes linked to leukocyte recruitment, bronchoconstriction, mucus secretion, vascular permeability, and acute inflammation[2]. In disease models, FLAP-deficient and 5-LO-deficient mice showed impaired leukotriene production and reduced responses in arachidonic acid- and zymosan A-induced inflammation, supporting 5-LOX pathway relevance for experimental inflammation design[2]. Compared with 12/15-lipoxygenase enzymes, which oxidize fatty acids to bioactive lipid metabolites across multiple disease states, 5-LOX is distinguished by its FLAP-dependent leukotriene pathway and direct role in intact-cell leukotriene synthesis[3][4]. For experimental applications, direct 5-LOX inhibitors and FLAP-targeting compounds help test whether leukotriene biosynthesis drives inflammatory phenotypes in cellular or animal models[1][4].